Performance evaluation of the COBAS/TaqMan HIV-1 v2.0 in HIV-1 positive patients with low viral load: A comparative study

Journal of Virological Methods

Volumn 173, Issue 2, 2011, Pages 399-402

  Paba, Pierpaolo ^a   Fabeni, Lavinia ^a   Ciccozzi, Massimo ^b   Perno, Carlo Federico ^a   Ciotti, Marco ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

HIV 1; Low viral load; Real time PCR

Indexed keywords

VIRUS RNA;

ACCURACY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION; VIRUS DETECTION; VIRUS LOAD;

DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MOLECULAR DIAGNOSTIC TECHNIQUES; PLASMA; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; STATISTICS AS TOPIC; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 79954588023     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.03.014     Document Type: Article

References (15)

1. Bagchi S., Kempf M.C., Westfall A.O., Maherya A., Willing J., Saag M.S. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?. Clin. Infect. Dis. 2007, 44:135-138.
2. Di Mascio M., Markowitz M., Louie M., Hurley A., Hogan C., Simon V., Follmann D., Ho D.D., Perelson A.S. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection. J. Virol. 2004, 78:10566-10573.
3. Gatanaga H., Tsukada K., Honda H., Tanuma J., Yazaki H., Watanabe T., Honda M., Teruya K., Kikuchi Y., Oka S. Detection of HIV TYPE 1 LOAD BY THE Roche Cobas TaqMan assay in patients with viral loads previously undetectable by Roche Cobas Amplicor Monitor. Clin. Infect. Dis. 2009, 48:260-262.
4. Gross R., Bilker W.B., Friedman H.M., Strom B.L. Effect of adherence to newly antiretroviral therapy on plasma viral load. AIDS 2001, 15:2109-2117.
5. Lima V., Harrigan R., Montaner J.S. Increased reporting of detectable plasma HIV-1 RNA levels at critical threshold of 50 copies per millilitre with the Taqman assay in comparison to the Amplicor assay. J. Acquir. Immune Defic. Syndr. 2009, 51:3-6.
6. Manavi K. The significance of low-level plasma HIV viral load on Cobas TaqMan HIV-1 assays for patients with undetectable plasma viral load on COBAS Amplicor monitor version 1.5. HIV Clin. Trials 2008, 9:283-286.
7. Mellors J.W., Muñoz A., Giorgi J.V., Margolick J.B., Tassoni C.J., Gupta P., Kingsley L.A., Todd J.A., Saah A.J., Detels R., Phair J.P., Rinaldo C.R. Plasma viral load and cd4+ lymphocytes markers of HIV-1 infection. Ann. Intern. Med. 1997, 126:946-954.
8. Peeters M., Aghokeng A.F., Delaporte E.E. Genetic diversity among human immunodeficiency virus-1 non-B subtypes in viral load and drug resistance assays. Clin. Microbiol. Infect. 2010, 16:1525-1531.
9. Pereyra F., Palmer S., Miura T., Block L.B., Wiegand A., Rothchild A.C., Baker B., Rosenberg R., Cutrel E., Seaman M.S., Coffin J.M., Walker B.D. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 2009, 200:984-990.
10. Peter J.B., Sevall J.S. Molecular-based methods for quantifying HIV viral load. AIDS Patients Care STDS 2004, 18:75-79.
11. Rebeiro P.F., Kheshti A., Bebawy S.S., Stinnette S.E., Erden H., Tang Y., Sterling T.R., Raffanti S.P., D'Aquila R.T. Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures. Clin. Infect. Dis. 2008, 47:1354-1357.
12. Shain E.B., Clemens J.M. A new method for robust quantitative and qualitative analysis of real-time PCR. Nucleic Acids Res. 2008, 36:e91.
13. Sloma C.R., Germer J.J., Gerards T.M., Madrekar J.N., Mitchell P.S., Yaho J.D. Comparison of the Abbott realtime human immunodeficiency virus type 1 (HIV-1) assay to the Cobas Ampliprep/Cobas TaqMan HIV-1 test: workflow, reliability, and direct costs. J. Clin. Microbiol. 2009, 47:889-895.
14. Smit E., Bhattachrya S., Osman H., Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplcor to Cobas Taqman assay. J. Acquir. Immune Defic. Syndr. 2009, 51:364-365.
15. Wirden M., Tubiana R., Marguet F., Leroy I., Simon A., Bonmarchand M., Ait-Arkoub Z., Murphy R., Marcelin A.G., Katlama C., Calvez V. Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes. J. Clin. Microbiol. 2009, 47:1543-1545.